Chelsea Therapeutics, Inc. Receives Notice of Allowance of Key U.S. Patent for Novel, Controlled Release Formulation of Northera(TM)

CHARLOTTE, N.C., Dec. 15, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) received a notice of allowance from the U.S. Patent & Trademark Office (USPTO) for its patent application “Threo-DOPS Controlled Release Formulation,” U.S. Patent Application Number 11/698,974. Upon issuance, the patent will expire no earlier than 2026.